|
1
|
Couri T and Pillai A: Goals and targets
for personalized therapy for HCC. Hepatol Int. 13:125–137. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang JD, Hainaut P, Gores GJ, Amadou A,
Plymoth A and Roberts LR: A global view of hepatocellular
carcinoma: Trends, risk, prevention and management. Nat Rev
Gastroenterol Hepatol. 16:589–604. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang J, Tang M, Huang Z and Chen L:
Junctophilins emerge as novel therapeutic targets. J Cell Physiol.
234:16933–16943. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Margolis RL and Rudnicki DD: Pathogenic
insights from Huntington's disease-like 2 and other Huntington's
disease genocopies. Curr Opin Neurol. 29:743–748. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu X, Kuang Y, Li L, Tang H, Shi Q, Shu X,
Zhang Y, Chan FK, Tao Q and He C: Epigenomic and functional
characterization of junctophilin 3 (JPH3) as a novel tumor
suppressor being frequently inactivated by promoter CpG methylation
in digestive cancers. Theranostics. 7:2150–2163. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han TS, Ban HS, Hur K and Cho HS: The
epigenetic regulation of HCC metastasis. Int J Mol Sci.
19:39782018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dawson MA and Kouzarides T: Cancer
epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nebbioso A, Tambaro FP, Dell'Aversana C
and Altucci L: Cancer epigenetics: Movin forward. PLoS Genet.
14:e10073622018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang L, Lu Q and Chang C: Epigenetics in
health and disease. Adv Exp Med Biol. 1253:3–55. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang D, Zhao J, Han C, Liu X, Liu J and
Yang H: Identification of hub genes related to prognosis in glioma.
Biosci Rep. 40:BSR201933772020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen KH, He J, Wang DL, Cao JJ, Li MC,
Zhao XM, Sheng X, Li WB and Liu WJ: Methylation-associated
inactivation of LATS1 and its effect on demethylation or
overexpression on YAP and cell biological function in human renal
cell carcinoma. Int J Oncol. 45:2511–2521. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huang A, Yang XR, Chung WY, Dennison AR
and Zhou J: Targeted therapy for hepatocellular carcinoma. Signal
Transduct Target Ther. 5:1462020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang Y, Han QJ and Zhang J:
Hepatocellular carcinoma: Mechanisms of progression and
immunotherapy. World J Gastroenterol. 25:3151–3167. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berger MF and Mardis ER: The emerging
clinical relevance of genomics in cancer medicine. Nat Rev Clin
Oncol. 15:353–365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zahn LM: Effects of the tumor
microenvironment. Science. 355:1386–1388. 2017. View Article : Google Scholar
|
|
18
|
Villanueva A: Hepatocellular carcinoma. N
Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie DY, Ren ZG, Zhou J, Fan J and Gao Q:
2019 Chinese clinical guidelines for the management of
hepatocellular carcinoma: Updates and insights. Hepatobiliary Surg
Nutr. 9:452–463. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ganne-Carrié N and Nahon P: Hepatocellular
carcinoma in the setting of alcohol-related liver disease. J
Hepatol. 70:284–293. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Skvortsova K, Stirzaker C and Taberlay P:
The DNA methylation landscape in cancer. Essays Biochem.
63:797–811. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edwards JR, Yarychkivska O, Boulard M and
Bestor TH: DNA methylation and DNA methyltransferases. Epigenetics
Chromatin. 10:232017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee J, Kim Y, Friso S and Choi SW:
Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med.
54:78–88. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan Y, Liu G, Zhou F, Su B and Li Y: DNA
methylation profiles in cancer diagnosis and therapeutics. Clin Exp
Med. 18:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dor Y and Cedar H: Principles of DNA
methylation and their implications for biology and medicine.
Lancet. 392:777–786. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Toh TB, Lim JJ and Chow EK: Epigenetics of
hepatocellular carcinoma. Clin Transl Med. 8:132019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Raggi C and Invernizzi P: Methylation and
liver cancer. Clin Res Hepatol Gastroenterol. 37:564–571. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nakamura M, Chiba T, Kanayama K, Kanzaki
H, Saito T, Kusakabe Y and Kato N: Epigenetic dysregulation in
hepatocellular carcinoma: An up-to-date review. Hepatol Res.
49:3–13. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maemura K, Yoshikawa H, Yokoyama K, Ueno
T, Kurose H, Uchiyama K and Otsuki Y: Delta-like 3 is silenced by
methylation and induces apoptosis in human hepatocellular
carcinoma. Int J Oncol. 42:817–822. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Acun T, Oztas E, Yagci T and Yakicier MC:
SIP1 is downregulated in hepatocellular carcinoma by promoter
hypermethylation. BMC Cancer. 11:2232011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pastushenko I and Blanpain C: EMT
transition states during tumor progression and metastasis. Trends
Cell Biol. 29:212–226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Saitoh M: Involvement of partial EMT in
cancer progression. J Biochem. 164:257–264. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Aiello NM and Kang Y: Context-dependent
EMT programs in cancer metastasis. J Exp Med. 216:1016–1026. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo F, Wang H, Jiang M, Yang Q, Xiang Q,
Zhou H, Hu X, Hao K, Yang J, Cao H and Shen Z: TDP-43 induces EMT
and promotes hepatocellular carcinoma metastasis via activating
Wnt/β-catenin signaling pathway. Am J Cancer Res. 10:3285–3301.
2020.PubMed/NCBI
|
|
35
|
Lu J, Zhao Z and Ma Y: miR-186 represses
proliferation, migration, invasion, and EMT of hepatocellular
carcinoma via directly targeting CDK6. Oncol Res. 28:509–518. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dian MJ, Li J, Zhang XL, Li ZJ, Zhou Y,
Zhou W, Zhong QL, Pang WQ, Lin XL, Liu T, et al: MST4 negatively
regulates the EMT, invasion and metastasis of HCC cells by
inactivating PI3K/AKT/Snail1 axis. J Cancer. 12:4463–4477. 2021.
View Article : Google Scholar : PubMed/NCBI
|
